exarafenib

Exarafenib is an orally available, highly selective pan-RAF inhibitor that targets class I, II, and III B-Raf (BRAF) protein kinases. It is a small molecule designed to inhibit BRAF-driven signaling in cancers with various classes of BRAF mutations—including those for which no approved therapies currently exist (class II and III). By binding to mutant forms of the BRAF kinase, exarafenib blocks the RAF/MEK/ERK pathway, thereby inhibiting tumor cell proliferation and survival. Exarafenib has shown early clinical activity in patients with solid tumors harboring BRAF or NRAS mutations. The drug was originally developed by Kinnate Biopharma and later acquired by Pierre Fabre Laboratories[1][4][5][6][8].

Brand names

exarafenib

Other names

exarafenib hydrochloride